InMode (INMD) Q1 2026 Earnings Call Transcript

InMode reported Q1 revenue of $82 million, up 5% year over year, but margins and EPS softened: GAAP gross margin fell to 75% from 78%, non-GAAP operating margin declined to 17% from 23%, and non-GAAP EPS was $0.25 versus $0.31. Management guided 2026 revenue to $365 million-$375 million and non-GAAP EPS to $1.33-$1.38, while continuing aggressive buybacks and exploring M&A. The company also highlighted early North America reorganization benefits, new international subsidiaries, and the pending Erbium laser launch.

Analysis

The core read-through is not the modest top-line beat; it is that InMode is transitioning from a margin-expansion story to a mix-and-execution story. When a device company leans harder into newer platforms and direct-sales reorganization at the same time, gross margin pressure often shows up before revenue acceleration does, so the market is likely to trade the next 2-3 quarters on whether U.S. stabilization is real rather than on the current quarter itself. That makes the stock less about near-term EPS optics and more about whether management can re-accelerate utilization of the installed sales force without another step-down in margin.

The second-order dynamic is competitive: if InMode’s one-stop-shop positioning works, smaller single-product aesthetic vendors are the most vulnerable because physicians prefer fewer vendors and more bundled workflows. But that same bundling logic is exactly why the company is accepting lower near-term profitability; the risk is that competitors with pharma/injectable exposure can defend the physician wallet share more efficiently, especially as GLP-1 and other consumables divert discretionary spend away from energy-based devices. In other words, the bull case requires not just stabilizing demand, but proving that InMode can win share in a shrinking addressable spend pool.

The balance sheet and buyback cadence are the real near-term support under the stock, but the quality of capital return matters here. With operating cash flow still positive and a large net cash position, buybacks can cushion downside over the next few months, yet they do not fix the strategic question of whether product innovation or M&A is the better use of capital. The leadership transition adds a modest governance overhang: if CFO continuity weakens around a period of restructuring, the market may discount guidance more heavily even if fundamentals are stable.

Contrarian view: consensus may be too quick to extrapolate the margin compression as structural deterioration. If the new U.S. sales model and separate Envision team show even incremental traction into Q2/Q3, the multiple can re-rate sharply because this is still a high-cash-flow name with a large buyback engine. The cleaner tell will be whether revenue inflects faster than operating expense growth; if it does, the current drawdown likely underprices the optionality from Argentina, China, and the next laser cycle.

Key Decisions for Investors

• Long INMD into the next 1-2 quarterly prints with a 6-9 month horizon; risk/reward favors upside if U.S. stabilization and product-mix execution improve, but size modestly because gross margin is still trending down.
• Use a call spread in INMD (6-12 months out) rather than outright stock if you want exposure to a re-rating from execution improvements; the asymmetry is better if buybacks continue to support downside.
• Pair trade: long INMD / short a single-product aesthetic device peer or a consumables-heavy aesthetic name for 3-6 months; the thesis is that bundled platforms and sales-force leverage should outperform weaker, narrower franchises.
• If INMD rallies on buyback headlines without revenue acceleration, fade strength with a tight stop; the market can overprice capital returns when the bigger issue is demand durability.
• For event-driven traders, buy on any post-earnings pullback only if management reiterates 74%-76% gross margin and Q2 proves Argentina/Envision are contributing; otherwise wait for a cleaner catalyst because the next leg depends on evidence, not narrative.